Regulatory milestones

Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.19 (47%) to $2.44 on Friday, which translates to a loss in market cap of $391.4 million, after FDA's Vaccines and Related Biological Products Advisory Committee voted 8-5 with one abstention on Thursday that the company had not gathered enough safety data to support approval of Heplisav, an adjuvanted vaccine for HBV. The PDUFA date is Feb. 24 (see B12).